Healthcare shares were generally mixed in pre-market trade on Friday.
In healthcare stocks news, biotechnology company Advaxis ( ADXS ) released preliminary data from an ongoing Phase 1 clinical study of its ADXS-cHER2 cancer therapy in dogs with osteosarcoma showing the treatment is able to delay or prevent metastatic disease and significantly prolong overall survival in dogs with osteosarcoma that had minimal residual disease following standard of care.
The company said 80% of the dogs treated were still alive and median survival hadn't yet been reached; the median survival in control dogs was 316 days.
Analysts at Barclays initiated coverage of Sabra Healthcare REIT ( SBRA ) with an equalweight rating and a price target of $31 a share.
SBRA is a subsidiary of Sun Healthcare Group, Inc., a provider of nursing, rehabilitative and related specialty healthcare services.
SBRA was unchanged from Thursday's close at $29.67, and move within a 52-week spread of $21.55 - $31.17.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
